1. Overview
  2. All Stocks
  3. Zomedica Corp.

Zomedica (ZOMDF.US) – Strong Sell: Rating and Stock Analysis 2026/2027

0,09
-3,44%
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Share this analysis:

No analysts currently cover Zomedica with a public price target. We add the price target automatically as soon as at least one analyst publishes a rating. Until then, use the technical analysis and the key figures below.

About Zomedica – Medicinprodukter

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. The company provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, Assisi EquiLoop, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Read more about the company

Key Figures for Zomedica

$ 84,3M Market cap
$ 34,3M Revenue
Medicinprodukter Industry
- P/E
2.45 P/S
0.79 P/B
USA Listed on exchange
zomedica.com Website
Sundhed Sector

What kind of stock is Zomedica?

Speculative stock

Zomedica is classified as a speculative stock.

Score Overview for Zomedica

💰 Value Score 43/100 (Neutral)
⭐ Quality Score 5/100 (Very Low)
🚀 Momentum Score 17/100 (Very Low)
📊 Total Score 21/100

⚠️ 3 red flags identified 1 critical

Our analysis has identified 3 potential risk factors in Zomedica that investors should be aware of.

⚠️ Weak financial health: The Piotroski score is only 2/9 – the company shows signs of weakened profitability, liquidity or capital structure.
🚨 Negative profit margin: The profit margin is -65.8% – the company is losing money on its operations.
⚠️ Negative return on equity: ROE is -18.6% – the company is generating a negative return for shareholders.

📈 Valuation

The P/S ratio is 2.5. The P/B ratio is 0.8, below book value, which can point to a value opportunity.

🏦 Financial Health

The Piotroski score is 2 out of 9 — weak financial health, be careful. The debt-to-equity ratio (D/E) is 6.0% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 4.71%.

↑ Back to navigation

Zomedica Short Selling 2026: 4.7% Sold Short

Moderate short interest: 4.7% of the free float
Short % of free float
4.7%
Assessment
Moderate short interest
Short squeeze risk
Low
Data source
SEC
Updated daily
The stock has a moderate share of short selling. Between 2-5% of the freely traded shares are sold short, which is within the normal range for most stocks.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
4.7%

↑ Back to navigation

Zomedica Earnings – ⚡ Reporting TODAY 8/6/2026

The next earnings date for Zomedica is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of Zomedica 2026 – Signal: Strong Sell

Overall Technical Signal: Strong Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Trend Analysis of Zomedica Corp.

Zomedica Corp. is in a short-term uptrend. The price of $0.09 is 2.3% above the 20-day average ($0.09). Medium term, the picture is negative: the price is 4.3% below the 50-day average ($0.09). Long term, the stock is 17.8% below the 200-day average ($0.11), which signals a long-term downtrend.

Death Cross: The 50-day average (0.09) is below the 200-day average (0.11), which is a classic bearish signal for Zomedica Corp..

Is Zomedica Corp. overbought or oversold?

Zomedica Corp. has an RSI of 49.0, right in the middle of the neutral zone. There is no clear buying or selling pressure.

MACD Analysis for Zomedica Corp.

Daily MACD: MACD is negative (-0.001), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-0.002) by 0.001, which suggests the negative momentum is fading – a potential trend reversal could be ahead.

Weekly MACD: MACD5 is negative (-0.005), which indicates a broader bearish long-term trend. MACD5 is below the signal line (-0.002) by 0.003, which confirms continued negative long-term momentum.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Zomedica Corp.

Zomedica Corp. has an annual standard deviation of 88.8%, which classifies the stock as extreme risk. Only risk-tolerant investors should consider this stock, because the price swings can be very large.

Overall Technical Conclusion for Zomedica Corp.

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-0.001). Weekly bearish (-0.005).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 49.0 – neutral.

Technical signal: Strong Sell

The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.

↑ Back to navigation

Frequently Asked Questions About Zomedica stock in 2026

Should you buy Zomedica stock now?
No, the technical signal for Zomedica is currently SELL. Zomedica trades at $0.09 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.001 with rising momentum (signal: -0.002); RSI is at 49.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average). The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Zomedica stock?
There is currently no active analyst price target for Zomedica.
Is Zomedica a dividend stock?
No, Zomedica does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Zomedica stock?
Zomedica is rated as a stock with extreme risk. the annual standard deviation is 88.8%, which classifies the stock as extreme risk.
Is Zomedica overvalued?
Zomedica has the following valuation ratios: a P/S ratio of 2.5, a P/B ratio of 0.8.
Is Zomedica overbought?
No, Zomedica is not overbought. RSI is at 49.0 (neutral zone). The technical indicators show: RSI is at 49.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.0% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Zomedica earnings report?
Zomedica reports earnings TODAY, August 6, 2026! The stock currently trades at $0.09. Watch how the price reacts after the release.
Is Zomedica shorted?
Yes, Zomedica is shorted with 4.7% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Zomedica stock?
There is currently no registered insider trading for Zomedica.
Is Zomedica a good stock?
Based on our total score, Zomedica is rated as a poor stock with a total score of 22 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 43/100, Quality: 5/100, Momentum: 17/100. In addition: technical signal: Strong Sell. Whether Zomedica is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Zomedica stock?
The outlook for Zomedica based on current data: the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Zomedica stock moving?
Zomedica is stable right now. The technical indicators show: the price is close to the 20-day average. For the latest context, see our technical analysis, insider section and news overview above.
How high can Zomedica go?
There is currently no active analyst price target for Zomedica. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Zomedica fall?
We lack enough history to give a specific floor for Zomedica. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Zomedica do?
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. It offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Zomedica as an investment.
Did Zomedica raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Zomedica. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Zomedica making money or losing money?
No, Zomedica is currently not making money — the company is losing money with a negative profit margin of -65.8%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Zomedica go bankrupt?
We have no current data to calculate the bankruptcy risk for Zomedica. Check the latest report and the debt level in the key figures section above.
Does Zomedica have a lot of debt?
No, Zomedica has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 6%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More